Enanta Pharmaceuticals Inc

This proposal asks shareholders to approve a discrete increase of 1,600,000 shares to the reserve under Enanta’s 2019 Equity Incentive Plan. Management seeks approval because equity awards are a central part of the company’s compensation framework used broadly across employees to align incentives and retain talent, and the Compensation Committee projects current available shares would be insufficient to support customary annual grants. The company documents its historical burn rate (three‑year average net burn of 4.1%) and argues the requested increase represents roughly one year of retention awards (5.5% of outstanding shares as of Dec 31, 2025). Approval is also necessary to satisfy Nasdaq listing rules and to preserve favorable tax treatment for incentive stock options under Section 422 of the Code. The board recommends FOR the amendment, emphasizing competitive hiring/retention needs during a critical growth period and noting the plan’s governance controls (Compensation Committee administration, limits on repricing without shareholder approval). Key contextual risks are dilution to existing holders and the potential for larger-than-expected equity expense if many awards vest or are granted; the company attempts to mitigate this by describing historical burn management and use of performance-based awards. From a governance perspective shareholders will want to weigh the quantified increase versus the company’s disclosed burn metrics, the use of performance-based PSUs and rTSRUs, and how the additional reserve might be allocated between employees, executives, and directors. If approved, the company intends to file a Form S-8 to register the additional shares for issuance.

This management-sponsored advisory proposal asks shareholders to endorse, on a non-binding basis, the company’s compensation decisions for its named executive officers as disclosed in the proxy statement. Management frames the vote as an annual opportunity for shareholders to communicate support or concerns: the board previously adopted an annual frequency following shareholder input. The Compensation Committee emphasizes a pay-for-performance program that relies heavily on long-term equity (time-based options, performance share units and relative TSR units), benchmarking to a peer group, and multi-year performance metrics tied to R&D and clinical milestones. Management notes high prior shareholder support (approximately 93% at the 2025 meeting) and states the Committee will consider the outcome of the advisory vote in future compensation decisions, but the vote is non-binding. Key issues for evaluators include the balance between fixed salary, variable cash incentives, and equity; the use of two‑year PSU and rTSRU performance periods tied to internal clinical/research milestones and relative TSR; and the potential for large equity dilution or retention-driven awards. The board recommends FOR given its view that compensation aligns management incentives with long‑term shareholder value, but shareholders may assess execution history, the rigor of performance measures, and whether disclosed outcomes justify continued endorsement. For sophisticated reviewers, the proposal is best judged in the context of the company’s recent performance against stated milestones, the realized payouts on prior PSUs/rTSRUs, and the transparency of goal-setting and disclosure.